Clinical Trials
SIDNEY – EO2463 in Indolent non-Hodgkin lymphoma
SIDNEY (EONHL1-20) is a multicenter, open-label, first-in-human, Phase 1/2 study of EO2463 as monotherapy and in combination with lenalidomide and/or rituximab for the treatment of patients with indolent non-Hodgkin lymphoma (iNHL).
The study aims to assess safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 monotherapy and combination therapy in approximately 60 patients with follicular lymphoma (FL) and marginal zone lymphoma (MZL).
ClinicalTrials.gov Identifier: NCT04669171
ROSALIE – EO2401 in glioblastoma
ROSALIE (EOGBM1-18) is a multicenter, open-label, first-in-human, Phase 1/2 study of EO2401 in combination with an immune checkpoint inhibitor (nivolumab, Opdivo®) +/- bevacizumab for the treatment of patients with first progression/recurrence of glioblastoma (GB).
The study assessed the safety, tolerability, immunogenicity, and preliminary efficacy of the combination in 100 patients at 10 clinical sites in Europe and the US.
Clinical data from the ROSALIE study have been presented in both poster and oral formats at several congresses, including the Society for Neuro-Oncology (SNO) Annual Meeting, the American Society of Clinical Oncology (ASCO) Annual Meeting, the Society for Immunotherapy of Cancer (SITC) Annual Meeting, and the European Society for Medical Oncology (ESMO) Congress.
ClinicalTrials.gov Identifier: NCT04116658
SPENCER – EO2401 in adrenal tumors
SPENCER (EOADR1-19) is a multicenter, open-label Phase 1/2 study of EO2401 in combination with the immune checkpoint inhibitor nivolumab for the treatment of patients with locally advanced or metastatic adrenocortical carcinoma or malignant pheochromocytoma/paraganglioma.
The study aims to assess the safety, tolerability, immunogenicity, and preliminary efficacy of this combination as a first- and second-line treatment in approximately 120 patients enrolled at up to 20 clinical sites across Europe and the U.S.
Clinical data from the study have been presented at the European Network for the Study of Adrenal Tumours (ENS@T), SITC, ASCO and ESMO.
ClinicalTrials.gov Identifier: NCT04187404
AUDREY – EO4010 in metastatic colorectal cancer
AUDREY (EOCRC2-22) is an open label, multicenter, first-in-human, phase 1/2 trial to assess safety, tolerability, immunogenicity, and preliminary efficacy of the peptide-based immunotherapy EO4010 in combination with an immune checkpoint inhibitor (nivolumab, Opdivo®) for treatment of patients with unresectable, previously treated, metastatic colorectal cancer.
The study aims to assess immunogenicity and preliminary efficacy of EO4010, in combination with nivolumab, and in monotherapy, in 42 patients with previously treated, metastatic colorectal carcinoma.
ClinicalTrials.gov Identifier: NCT05589597